Evidence map›Paper›PMID 42635425›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Identification of a candidate PRODH allosteric inhibitor MBTP-15324: modulation of proline metabolite profiles and ECM-associated gene-expression changes in lung cancer cells.

Yuxuan Zhou, Dingyuan Bai, Zhihan Li, Ciqin Li, Chunqiong Li, Mengyao Chen, Cheng Guo, Jun Yan, Yonglong Han, Quanjun Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuxuan ZhouCollege of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Dingyuan BaiCollege of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Zhihan LiDepartment of Pharmacy, Shanghai Sixth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ciqin LiDepartment of Pharmacy, Shanghai Sixth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chunqiong LiInstitute of Molecular Medicine, College of Future Technology, Peking University, Beijing, China.
Mengyao ChenCollege of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Cheng GuoDepartment of Pharmacy, Shanghai Sixth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-0762-8496
Jun YanCollege of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Yonglong HanCollege of Food Science and Technology, Shanghai Ocean University, Shanghai, China.ORCID 0000-0001-8655-5805
Quanjun YangCollege of Food Science and Technology, Shanghai Ocean University, Shanghai, China.ORCID 0000-0003-0279-8784

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current proline dehydrogenase (PRODH) inhibitors lack scaffold diversity. Through virtual screening, microscale thermophoresis, and molecular dynamics simulations, we identified MBTP-15324 as a candidate novel PRODH allosteric inhibitor (Kd = 1.45 μM). In PRODH-overexpressing lung cancer cells (A549 and LLC), MBTP-15324 significantly attenuated cell viability, colony formation, and migration. Furthermore, multi-omics analyses revealed that this putative inhibitor partially reversed arginine-proline metabolic dysregulation and downregulated transcriptional programs associated with inflammation, cell adhesion, and the extracellular matrix (ECM). In conclusion, MBTP-15324 provides a novel-scaffold chemical starting point for future PRODH-targeted therapies and metabolic interventions in lung cancer.

Indexed as

Antineoplastic AgentsEnzyme InhibitorsExtracellular MatrixLung NeoplasmsProlineProline OxidaseAllosteric RegulationCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsEnzyme InhibitorsPRODH protein, humanProlineProline Oxidasecandidate allosteric inhibitorextracellular matrix (ECM)lung cancerProline dehydrogenase (PRODH)proline metabolism

Identifiers

PMID42635425
PMCPMC13508488

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.